MDNews - Lower Hudson/Bronx

May 2016

Issue link: https://viewer.e-digitaledition.com/i/674623

Contents of this Issue

Navigation

Page 6 of 23

against PSA screening a very dangerous one," he says. "If we stop PSA screen- i ng , t here is not h i ng to stop h istor y from repeating itself. Men a re going to present with metastatic disease and die. However, we a lso have to recognize that the PSA test does have limitations. To effectively use the tool of PSA screening a nd g uide ca re appropriately, we have to understa nd that prostate ca ncer is a spectrum of disease." Dr. Benson describes two hy potheti- ca l men. One is 88, lives in a nursing home and dies after complications from a fa ll. An autopsy discovers microscopic levels of ca ncer in his prostate. He had t he disea se, but it wa s not clinica l ly sig nif ica nt a nd in a ll likelihood, never would have been. The second scena rio highlights the opposite end of the disease spectrum. A 45-yea r-old ma n develops a n aggres- sive form of prostate ca ncer. If it isn't discovered, treated a nd cured in a timely ma nner, the likelihood of the disease meta sta sizing elsewhere in the body a nd threatening his life is ex tremely high. In this scena rio, a PSA test leading to biopsy, a na lysis, diagnosis a nd ta rgeted therapy would likely be the most effective path to saving his life. So what is the difference? Both men had the sa me disease, but their clinica l needs a nd the appropriate medica l responses to the disease itself a re vastly different. Even if the f irst ma n's ca ncer had been identif ied during his lifetime, invasive ca re would have been inappropriate. The prog ra m at N Y P/Law rence is desig ned to meet the needs of patients whose cases fa ll at either end of this spectrum A Record of Excellence PRIOR TO JOINING NewYork-Presbyterian/Lawrence in December 2015, Mitchell C. Benson, MD, served on staff at NewYork- Presbyterian/Columbia University Medical Center. There, he was chair of the Department of Urology from 2005 to 2013 and director of the Comprehensive Cancer Center from 2003 to 2005. Dr. Benson is a Herbert and Florence Irving Professor of Urology at Columbia University as well as a member of ColumbiaDoctors. "I successfully assisted in the development of the urology service line in my previous post and felt that my experience could be useful here at NewYork-Presbyterian/Lawrence as the program expanded," Dr. Benson says, explaining his decision to move his practice to Westchester County, where he now"sees patients as part of NewYork-Presbyterian Medical Group/Westchester. Dr. Benson has been on the leading edge of urologic care since early in his career. As a urologic oncology research fellow at Johns Hopkins Hospital and University, he was part of the group that developed the nerve-sparing radical prostatectomy procedure under the guidance of Patrick C. Walsh, MD. This approach dramatically enhanced the post-surgical outcomes of patients who underwent removal of the prostate, allowing many to retain sexual function at a time when this was consid- ered nearly impossible. "The nerve-sparing radical prostatectomy procedure was a great step forward in the treatment of prostate cancer," Dr. Benson says. "Similarly, the development of robot-assisted surgery changed the face of disease management in the field of urology. I consider myself an early converter to robot technol- ogy and have been using it to assist patients with urologic concerns for more than a decade." Chief Radiation Therapist Jill Giorgi, RTT, stands at the linear accelerator's (LINAC's) control console with Dr. Lee. Dr. Benson meets with a patient at his NewYork-Presbyterian Medical Group/Westchester office in Scarsdale. M D N E W S .C O M /// M D N E W S L O W E R H U D S O N / B R O N X ■ 2 016 0 7

Articles in this issue

Archives of this issue

view archives of MDNews - Lower Hudson/Bronx - May 2016